NCT02555969View on ClinicalTrials.gov

Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis

CompletedOBSERVATIONAL
Enrollment

56

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions
AmyloidosisPrimary Amyloidosis
Trial Locations (1)

02111

Tufts Medical Center, Boston

All Listed Sponsors
lead

Tufts Medical Center

OTHER

NCT02555969 - Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis | Biotech Hunter | Biotech Hunter